Avadel Pharmaceuticals

270 articles with Avadel Pharmaceuticals

• Avadel Pharmaceuticals Announces FDA Authorization to Import Tentatively-Approved LUMRYZ™ Ahead of Anticipated Final Approval Decision

  3/22/2023

  Avadel Pharmaceuticals plc today announced that the U.S. Food and Drug Administration (“FDA”) has approved its Pre-Launch Activities Importation Requests (PLAIR) for LUMRYZ.

• Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - March 21, 2023

  3/21/2023

  Avadel Pharmaceuticals plc announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to one new employee to purchase 15,000 ordinary shares under Avadel’s 2021 Inducement Plan.

• Avadel Pharmaceuticals Requests Final FDA Approval for LUMRYZ™ (sodium oxybate) extended-release oral suspension

  3/2/2023

  Avadel Pharmaceuticals plc announced today that it has submitted an amendment to the U.S. Food and Drug Administration (“FDA”) requesting final approval for LUMRYZ for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.

• Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - February 16, 2023

  2/16/2023

  Avadel Pharmaceuticals plc announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to two new employees to purchase an aggregate of 28,000 ordinary shares under Avadel’s 2021 Inducement Plan.

• Avadel Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

  2/8/2023

  Avadel Pharmaceuticals plc announced today that members of management will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15 at 1:00 p.m. ET.

• Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - February 3, 2023

  2/3/2023

  Avadel Pharmaceuticals plc today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to two (2) new employees to purchase an aggregate of 38,000 ordinary shares under Avadel’s 2021 Inducement Plan.

• Avadel Pharmaceuticals Announces Publication of Real-World Data Highlighting the Risk of Accidental Dosing Errors with Immediate-Release Twice-Nightly Oxybates

  1/24/2023

  Avadel Pharmaceuticals plc today announced the publication of real-world data describing the risk of accidental dosing errors with immediate-release twice-nightly oxybate.

• Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Jan 23, 2023

  1/23/2023

  Avadel Pharmaceuticals plc, a company focused on transforming medicines to transform lives, announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to three new employees to purchase an aggregate of 40,500 ordinary shares under Avadel’s 2021 Inducement Plan.

• Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

  1/10/2023

  Avadel Pharmaceuticals plc today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to six (6) new employees to purchase an aggregate of 105,000 ordinary shares under Avadel’s 2021 Inducement Plan.

• Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - December 19, 2022

  12/19/2022

  Avadel Pharmaceuticals plc announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to three new employees to purchase an aggregate of 42,500 ordinary shares under Avadel’s 2021 Inducement Plan.

• Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - December 01, 2022

  12/1/2022

  Avadel Pharmaceuticals plc, a company focused on transforming medicines to transform lives, announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to one new employee to purchase an aggregate of 30,000 ordinary shares under Avadel’s 2021 Inducement Plan.

• Avadel Pharmaceuticals to Present at Upcoming Investor Conferences - November 22, 2022

  11/22/2022

  Avadel Pharmaceuticals plc announced today that members of management will participate in the following upcoming investor conferences.

• Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - November 21, 2022

  11/21/2022

  Avadel Pharmaceuticals plc announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to one new employee to purchase an aggregate of 20,000 ordinary shares under Avadel’s 2021 Inducement Plan.

• Avadel Pharmaceuticals Announces Favorable Ruling on Motion to Delist REMS Patent from FDA’s Orange Book

  11/18/2022

  Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, announced that the United States District Court for the District of Delaware ordered Jazz Pharmaceuticals to delist U.S. Patent No. 8731963 from the U.S. Food and Drug Administration’s Orange Book.

• Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference

  11/10/2022

  Avadel Pharmaceuticals plc announced today that members of management will participate in a fireside chat at the Jefferies London Healthcare Conference on Thursday, November 17 at 2:40 p.m. GMT / 9:40 a.m. ET.

• Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2022 Financial Results

  11/9/2022

  Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the third quarter ended September 30, 2022.

• Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - November 07, 2022

  11/7/2022

  Avadel Pharmaceuticals plc announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to 2 new employees to purchase an aggregate of 130,000 ordinary shares under Avadel’s 2021 Inducement Plan.

• Avadel Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

  9/7/2022

  Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, announced that members of management will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on Wednesday, September 14 at 11:30 a.m. E.T.

• Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9

  8/2/2022

  Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:00 a.m. ET on Tuesday, August 9, 2022, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2022.

• 

  Avadel Sues HHS and FDA for Not Approving Narcolepsy Drug

  7/25/2022

  The complaint alleges the agencies made an error under the Administrative Procedure Act, violating the Food Drug and Cosmetics Act by failing to approve Lumryz.